Search Results for: Pharma: Other News to Note
-
Other News To Note
Astellas Pharma Canada Inc., of Markham, Ontario, and Theravance Inc., of South San Francisco, said that Health Canada has approved Vibativ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant and methicillin-susceptible strains...The product is intended to help to prevent the recurrence of skin cancers after surgical removal of the primary tumor -
On the March: Vaccines Make it Big After H1N1 Scare
And in other cancer vaccine news: Merck KGaA started a Phase III breast cancer trial with Stimuvax, Merck & Co...Other Phase III cancer vaccines include Merck KGaA and Oncothyreon Inc.'s Stimuvax, now in Phase III trials for both lung and breast cancer based on a Phase II lung cancer trial that failed but showed strong survival in a retrospective subset analysis -
On the March: Vaccines Make it Big After H1N1 Scare
And in other cancer vaccine news: Merck KGaA started a Phase III breast cancer trial with Stimuvax, Merck & Co...Other Phase III cancer vaccines include Merck KGaA and Oncothyreon Inc.'s Stimuvax, now in Phase III trials for both lung and breast cancer based on a Phase II lung cancer trial that failed but showed strong survival in a retrospective subset analysis -
Other News To Note
Sciele Pharma Inc., of Atlanta, a Shionogi company, has submitted a new drug application to the FDA for glycopyrrolate oral solution to treat chronic, moderate-to-severe drooling in pediatric patients...In other news, the company said it has validated the concept that its GlycoMim technology can inhibit the glucose transporter SGLT2 -
On the March: Vaccines Make it Big After H1N1 Scare
And in other cancer vaccine news: Merck KGaA started a Phase III breast cancer trial with Stimuvax, Merck & Co...Other Phase III cancer vaccines include Merck KGaA and Oncothyreon Inc.'s Stimuvax, now in Phase III trials for both lung and breast cancer based on a Phase II lung cancer trial that failed but showed strong survival in a retrospective subset analysis -
Other News To Note
To date, no adverse events have occurred in testing...BioAlliance Pharma SA, of Paris, said a U.S. District Court judge granted the motion to dismiss a civil action against the company and one of its executives filed by Eurofins Pharma US Holdings Inc., of Des Moines, Iowa, regarding the diagnostic technology Phenoscript, a test for HIV drug resistance -
Sentiment 'Swayze' Other Way in Pancreatic; Hopes Escalating
and partner Sanofi-Aventis Group decided to quit their Phase III trial with aflibercept (VEGF Trap) for first-line metastatic pancreatic cancer put new focus on the grim, quick-spreading tumor type, much in the news as a result of actor Patrick Swayze's death last week...15 research note, declaring the "tide is about to turn" for the company...With Abraxane in pancreatic cancer, the best news for Abraxis and patients - as well as Louisville, Colo.-based GlobeImmune, with GI-4000 - is the chance to -
Other News To Note
Clavis Pharma ASA, of Oslo, Norway, received a government grant of up to $1.1 million to accelerate the Phase II program with Intravenous CP-4126 in patients with newly diagnosed, advanced pancreatic cancer...LifeCycle Pharma AS, of Horsholm, Denmark, said that its board and Jim New have agreed to terminate New's contract, based on different views on how an international company based in Scandinavia should be managed -
Other News To Note
The treatment protocol, an open-label trial, is designed to allow physicians and other care providers to treat patients of Gaucher disease with prGCD during the expected shortage of Genzyme's Cerezyme and thereafter...TI Pharma, of Leiden, the Netherlands, said it has joined a new consortium to boost drug development for the treatment of two deadly diseases, African sleeping sickness and Leishmaniasis, which affect millions of people worldwide -
Other News To Note
BioAlliance Pharma SA, of Paris, said the national ethics committee has approved a Fentanyl Lauriad clinical trial application...DxS Ltd., of Manchester, UK, is working with London-based AstraZeneca plc to develop a companion diagnostic for use with Iressa (gefitinib) in non-small-cell lung cancer -
Other News To Note
DxS Ltd., of Manchester, UK, is working with London-based AstraZeneca plc to develop a companion diagnostic for use with Iressa (gefitinib) in non-small-cell lung cancer...Organon will continue to fund research through a wind-down period ending Dec. 31, and Ligand may receive up to several million dollars in milestones during that period -
Attention Shoppers: Antibody Prizes Not Limited to Medarex
Even though some analysts remain skeptical of ipilimumab's success in melanoma, particularly after Medarex's Pfizer Inc.-partnered antibody tremelimumab fizzled in the same indication last year, the drug has shown promise in other indications such as prostate and lung cancers...In addition to ipilimumab, the Medarex deal adds several other pipeline programs to BMS's arsenal -
Attention Shoppers: Antibody Prizes Not Limited to Medarex
topped its offer by $8 per share for a total purchase price of about $6.5 billion, but perhaps even then, it was eyeing its ipilimumab collaborator. (See BioWorld Today, Oct. 7, 2008.) Even though some analysts remain skeptical of ipilimumab's success in melanoma, particularly after Medarex's Pfizer Inc.-partnered antibody tremelimumab fizzled in the same indication last year, the drug has shown promise in other indications such as prostate and lung cancers...Inc. (See BioWorld Today, June 22 -
Other News To Note
The deal also is expected to expand the development of additional personalized tests for scoliosis, degenerative disc disease and other spine disorders...Under the terms, Merck gets a nonexclusive license plus other rights to certain Depomed patents in exchange for a $10 million up-front fee...Sirnaomics Inc., of Gaithersburg, Md., said it has received an Small Business Innovation Research grant from National Cancer Institute for its siRNA therapeutics to treat lung cancer -
Other News To Note
Axentis Pharma AG, of Zurich, Switzerland, said the FDA has granted a second orphan drug designation to Fluidosomes (tobramycin) as a treatment for pulmonary infections caused by Burkholderia cepacia pathogens in patients with cystic fibrosis...Financial terms were not disclosed, though CDI is allowed to sublicense rights to other companies and institutions -
Other News To Note
Galantos Pharma GmbH, of Mainz, Germany, said it was granted funding by the German Ministry for Education and Research under the KMU-Innovativ-2 program to support work on neuroprotective drugs for Alzheimer's disease...to develop products designed to advance the study of Alzheimer's disease...Targeted Genetics Corp., of Seattle, terminated the lease for its facility in Bothell, Wash., losing about $12 million in estimated payment obligations and other liabilities under the lease in exchange for a -
Other News To Note
Biopartners said it is on track to submit a European marketing authorization application in 2010...The REMS was formally submitted to the FDA on Dec. 12, 2008, and the submission was placed under a six-month review period...Noxxon Pharma AG, of Berlin, announced the initial dosing of healthy volunteers with its anti-inflammatory product Spiegelmer NOX-E36 in the company's first-in-human trial -
Other News To Note
In other news, the company appointed Anat Cohen-Dayag and Martin Gerstel as co-CEOs...CureVac GmbH, of Tuebingen, Germany, said it received approval to begin a Phase I study of its mRNA vaccine CV9201, in the treatment of advanced non-small-cell lung cancer -
Much-Awaited OncoGenex Data Heat Up Prostate Cancer Space
And, according to Simeonidis, big pharma and biotech already are watching, many representatives having attended OncoGenex's investor presentation Saturday...Now the pharma firm will take on "all the risk of making the jump from PSA response to overall survival," Rodman & Renshaw's Simeonidis wrote in a research note, adding that it's "not a slam-dunk, by any measure...Other ASCO news featured an immunotherapy for prostate cancer, not from Dendreon, which previously reported its data at the American -
Phase II Perifosine Data Send Keryx Shares Soaring 74%
A.P. Pharma Inc., of Redwood City, Calif., said data from its Phase III trial with APF530, sustained-release formulation of granisetron for the prevention of chemotherapy-induced nausea and vomiting, showed complete response rates for APF530 10 mg dose were noninferior to Aloxi (palonosetron, Eisai Co. Ltd.) during acute CINV (0 to 24 hours) following moderate or highly emetogenic chemotherapy and also during delayed CINV (24 to 120 hours), following moderately emetogenic chemo
Category
Current Filters
- xlung cancer
Related Keywords
Categories
- x BioWorld Today (364)
- x BioWorld International (108)
- x BioWorld Insight (6)
- x State of the Industry Report (4)
- x Bio Perspectives (3)
- x BioWorld Snapshots (1)